Document is current
Any future updates will be listed below
-
Authors
Greenwood, Heather I.
Maldonado Rodas, Cristian K.
Freimanis, Rita I. https://orcid.org/0000-0001-5229-8687
Glencer, Alexa C. https://orcid.org/0000-0002-3183-1056
Miller, Phoebe N. https://orcid.org/0000-0002-3938-3606
Mukhtar, Rita A. https://orcid.org/0000-0001-8079-7846
Brabham, Case
Yau, Christina
Rosenbluth, Jennifer M.
Hirst, Gillian L. https://orcid.org/0000-0002-4502-0035
Campbell, Michael J. https://orcid.org/0000-0002-3788-9240
Borowsky, Alexander https://orcid.org/0000-0003-3117-9202
Hylton, Nola https://orcid.org/0000-0002-6747-1662
Esserman, Laura J. https://orcid.org/0000-0001-9202-4568
Basu, Amrita https://orcid.org/0000-0001-5362-1343
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32CA251070-01, U01CA196406)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 19 March 2024
Accepted: 18 July 2024
First Online: 4 August 2024
Competing interests
: Laura Esserman is an unpaid member of the board of directors of Quantum Leap Healthcare Collaborative (QLHC) and received grant support from QLHC for the I-SPY2 Trial. She is also a member of the Blue Cross/Blue Shield Medical Advisory Panel and receives reimbursement for her time and travel. Dr. Esserman has received unrelated research support from Merck. Other authors report no competing interests.
